K-VOG 0.3MG TAB

Distributor inventory | Tablet

Type 2 diabetes mellitus (post‑prandial blood glucose control), used alone or as add‑on to other antidiabetic medicines along with diet and exercise

Voglibose is an alpha‑glucosidase inhibitor that delays the breakdown and absorption of carbohydrates in the small intestine. This reduces the rise in blood glucose after meals and improves post‑prandial glycaemic control.

Tablet; take exactly as prescribed, usually just before meals (or with the first bite of food). Swallow whole with water. Continue diet and exercise; do not stop or change dose without medical advice.

Flatulence, abdominal pain, diarrhoea, bloating, nausea

Not for type 1 diabetes or diabetic ketoacidosis. Use with caution in patients with intestinal obstruction, inflammatory bowel disease, colonic ulceration, malabsorption/chronic intestinal disorders. Monitor blood glucose and HbA1c regularly. When used with insulin or sulfonylureas, risk of hypoglycaemia increases—treat low sugar with glucose/dextrose (not sucrose). Use caution in liver disease; discontinue and seek care if severe abdominal symptoms occur.

Insulin, sulfonylureas (e.g., glimepiride/gliclazide) and other antidiabetics (increased hypoglycaemia risk); intestinal adsorbents/digestive enzyme preparations (may reduce effect); corticosteroids, thiazide diuretics, thyroid hormones, sympathomimetics (may increase glucose levels); alcohol (may affect glycaemic control)

Store below 25°C in a cool, dry place. Protect from moisture and direct light. Keep out of reach of children.

Voglibose 0.3 mg Tablet (generic), Vobose 0.3 Tablet, Vogli 0.3 Tablet, Volibo 0.3 Tablet, Voglitor 0.3 Tablet